[go: up one dir, main page]

MX2011012538A - Terapia de combinacion para el tratamiento del mieloma multiple. - Google Patents

Terapia de combinacion para el tratamiento del mieloma multiple.

Info

Publication number
MX2011012538A
MX2011012538A MX2011012538A MX2011012538A MX2011012538A MX 2011012538 A MX2011012538 A MX 2011012538A MX 2011012538 A MX2011012538 A MX 2011012538A MX 2011012538 A MX2011012538 A MX 2011012538A MX 2011012538 A MX2011012538 A MX 2011012538A
Authority
MX
Mexico
Prior art keywords
multiple myeloma
treatment
combination therapy
subject
combination
Prior art date
Application number
MX2011012538A
Other languages
English (en)
Inventor
James R Berenson
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/003467 external-priority patent/WO2010138101A1/en
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2011012538A publication Critical patent/MX2011012538A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee un método para el tratamiento de mieloma múltiple en un sujeto, que comprende la etapa de administrar al sujeto una combinación del compuesto 1 y bortezomib. La invención provee además un método para el tratamiento de mieloma múltiple en un sujeto, que comprende la etapa de administrar al sujeto una combinación del compuesto 1 y melfalán.
MX2011012538A 2009-05-27 2009-12-08 Terapia de combinacion para el tratamiento del mieloma multiple. MX2011012538A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18155009P 2009-05-27 2009-05-27
US18550109P 2009-06-09 2009-06-09
PCT/US2009/003467 WO2010138101A1 (en) 2009-05-27 2009-06-09 Combination therapy for the treatment of multiple myeloma using cep-18770 together with bortezomib or mephalan
US23259409P 2009-08-10 2009-08-10
PCT/US2009/067174 WO2010138141A1 (en) 2009-05-27 2009-12-08 Combination therapy for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
MX2011012538A true MX2011012538A (es) 2012-02-08

Family

ID=43222992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012538A MX2011012538A (es) 2009-05-27 2009-12-08 Terapia de combinacion para el tratamiento del mieloma multiple.

Country Status (7)

Country Link
US (1) US8765720B2 (es)
CN (1) CN102458127B (es)
AU (1) AU2009347159B2 (es)
CA (1) CA2763471A1 (es)
IL (1) IL216491A0 (es)
MX (1) MX2011012538A (es)
WO (1) WO2010138141A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022103B1 (pt) 2012-03-06 2022-04-19 The Board Of Trustees Of The University Of Illinois Composições e seus usos
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
US20190321345A1 (en) * 2016-12-28 2019-10-24 Emory University GLUT4 Selective Inhibitors for Cancer Therapy
WO2019099873A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
AU2019354771A1 (en) 2018-10-05 2021-04-01 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
US8894974B2 (en) * 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
EP2117556A2 (en) * 2007-01-23 2009-11-18 Gloucester Pharmaceuticals, Inc. Combination therapy comprising romidepsin and i.a. bortezomib
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy

Also Published As

Publication number Publication date
CN102458127B (zh) 2014-08-27
WO2010138141A1 (en) 2010-12-02
US8765720B2 (en) 2014-07-01
AU2009347159B2 (en) 2015-09-03
CN102458127A (zh) 2012-05-16
US20120071445A1 (en) 2012-03-22
IL216491A0 (en) 2012-01-31
CA2763471A1 (en) 2010-12-02
AU2009347159A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
AU2011328009A8 (en) Compounds and methods for treating pain
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
MX2011007930A (es) Conjugados de insulina cristalina.
MY183661A (en) Treatment of cancer with tor kinase inhibitors
WO2011020061A3 (en) Compositions and methods of for treating bipolar disorder
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
NZ601350A (en) Method of treating arthritis
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
NZ631144A (en) Compositions and methods for transmucosal absorption
PH12013501688A1 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2013098416A3 (fr) Composes anti-douleur
MX2011012131A (es) Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm).
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
PH12014502065A1 (en) Vesicular formulations
EP3449917A3 (en) Tapentadol for preventing chronification of pain
MX2009010164A (es) Metodo para tratar dolor mediado por el receptor cb2.
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
MX338595B (es) Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus.
MX2009010162A (es) Metodo para tratar dolor mediado por el receptor cb2.
MX2011005054A (es) Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple.
BR112012006073A2 (pt) composições e métodos para tratar espasticidade.
UA46514U (ru) Способ местного лечения ограниченной склеродермии

Legal Events

Date Code Title Description
FG Grant or registration